Fig. 2.

Partial response (PR) to nivolumab in 2 patients. a PET/CT of a 74 year-old male with metastatic dedifferentiated chondrosarcoma after six cycles of nivolumab alone; he is maintaining a PR after 26 cycles. b 46 years-old woman with osteosarcoma, treated with nivolumab for six cycles; pazopanib 800 mg p.o. daily was started after 4 cycles of nivolumab. She underwent resection with negative margins